Phase 2 randomised trial in 63 previously vaccinated healthy adults: a single GEO-CM04S1 COVID-19 booster at 1×10⁷ vs 1×10⁸ PFU was well tolerated with no vaccine-related serious adverse events; neutralising antibody and T-cell responses were comparable.
RCTn = 63
Ortega-Francisco et al. Phase 2 evaluation of two GEO-CM04S1 dose levels shows comparable safety and broad immunogenicity